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Background: The National Lung Screening Trial (NLST) and NELSON trial showed that low-dose chest computed tomography (LDCT) 
screening significantly reduced the mortality form lung cancer. Although cancer survivors are known to have high risk for second malignant 
neoplasm (SMN), the usefulness of LDCT screening for lung cancer in cancer survivors is not clear.
Methods: Between August 2016 and August 2017, 633 long-term colorectal cancer (CRC) survivors visited the survivorship clinic in Cancer 
Prevention Center, Yonsei Cancer Center, Seoul, Republic of Korea. We surveyed the smoking status and recommended LDCT screening 
to ever-smoking CRC survivors aged 55-80 years. The participants were classified into three risk groups: risk group 1 (RG1) who met 
the NLST criteria (Age 55-74 years, ≥ 30 pack-years of smoking, smoking cessation ＜ 15 years); risk group 2 (RG2) who would not 
meet the NLST criteria but were at increased 6-year risk of lung cancer (PLCOM2012 ≥ 0.0151); risk group 3 (RG3) who did not meet 
any of the criteria above.
Results: Among 176 ever-smoking CRC survivors, 173 (98.3%) were male, 32 (18.2%) were current-smoker, and median age was 66 
years (range, 55-79 years). We found 38 positive findings (non-calcified nodule ≥ 4 mm), 8 clinically significant findings, 66 minor 
abnormalities, and 64 negative findings on LDCT. Positive findings were identified in 15 of 79 (19.0%) of RG1, in 9 of 36 (25%) of 
RG2, and in 14 of 61 (23.0%) of RG3. Second primary lung cancers were found in 2 patients of RG2, and in 1 patient of RG3. SMN 
was most frequently found in RG2 (11 of 36 patients, 30.6%), compared with RG1 (12.7%) or RG3 (9.8%) (P = 0.016).
Conclusions: LDCT screening for lung cancer in Korean CRC survivors is feasible. Well-designed clinical trial for defining high risk patients 
for lung cancer among CRC survivors is needed.
(J Cancer Prev 2019;24:48-53)
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INTRODUCTION
Colorectal cancer is the second most common cancer and the 
fourth leading cause of cancer death in Korea [1]. With the recent 
advances in cancer screening and treatment, the number of 
long-term colorectal cancer survivors who lived longer than 5 
years from the time of diagnosis increased to 110,000 in Korea [1]. 
Among the cancer survivors, second malignant neoplasm (SMN) 
has become an important issue. National Cancer Institute’s 
Surveillance, Epidemiology, and End Results (SEER) reported that 
8% of cancer survivors developed SMN, and the risk was 14% 
higher compared to those in general population [2,3]. The 
occurrence of SMN is thought to be associated with treatment- 
related factors, lifestyle, environment, host factors, and 
genetics-environment [4]. In addition, because the frequency and 
clinical outcome of SMN is different according to the kinds of first 
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primary malignancy and SMN, personalized preventive strategies 
are needed. For colorectal cancer survivors, lung cancer was 
reported to be the second common SMN following prostate 
cancer [3]. Considering that lung cancer was the leading cause of 
mortality for SMN as well as first primary malignancy [3], proper 
screening program for lung cancer is necessary for management 
of colorectal cancer survivors.
In 2011, the National Lung Screening Trial (NLST) 
demonstrated that annual screening program with low-dose 
helical computed tomography (CT) in high risk patients could 
reduce 20% of mortality in consequence of lung cancer. Although 
several problems were proposed including overdiagnosis, 
cost-effectiveness, and long-term follow-up schedule, low-dose 
CT screening is currently recommended by the experts in many 
guidelines for the population with high risk for lung cancer [5-9]. 
In Korea, low-dose CT screening is recommended for the patients 
with high risk for lung cancer, and will be included in the national 
cancer screening program before the end of the year [10]. 
In this study, we conducted the lung cancer screening using 
low-dose chest CT in long-term colorectal cancer survivors with 
smoking history. We also tried to find the feasibility of low-dose 
CT screening in terms of lung-cancer risk groups, radiologic 
findings, and clinical outcome in the colorectal cancer survivors.
MATERIALS AND METHODS
1. Study population and definition
Between August 2016 and August 2017, we enrolled colorectal 
cancer survivors for long-term survivorship management in 
Cancer Prevention Center, Yonsei Cancer Center, Seoul, Republic 
of Korea. The eligibility criteria were as below: men and women 
aged 55 to 80 years of age; ever-smoker; histologically diagnosed 
colorectal cancer; survival more than 4 years from diagnosis of 
cancer; without evidence of known history of lung cancer and/or 
pulmonary metastases. The information about smoking was 
collected using verbal surveys: (1) smoking status; (2) smoking 
intensity; (3) smoking duration; (4) If the subject was a former 
smoker, duration of smoking cessation. Ever-smoker was defined 
as a subject who smoked at least 100 cigarettes in the lifetime. If 
the participant smoked cigarettes currently or during the last 30 
days, he or she was classified into a current smoker. Smoking 
intensity was defined as an average number of cigarettes smoked 
a day. If the patients expressed the number of cigarettes by pack, 
20 cigarettes were considered as a pack. Pack-years was calculated 
by multiplying smoking intensity in pack by smoking duration in 
year. Clinical characteristics were collected using electronic 
medical record. This study was approved by Institutional Review 
Board at Severance Hospital, Seoul, Korea (IRB approval number 
4-2016-0522). 
2. Radiologic and clinical outcome measurement
We recommended the ever-smoking colorectal cancer 
survivors to receive low-dose chest CT screening for lung cancer. 
For the patient who agreed to the lung cancer screening, low-dose 
CT was performed on multidetector helical CT scanners of four 
channels. On the low-dose CT images, noncalcified nodules with 
long-axis diameters of 4 mm or greater in the axial plane, 
adenopathy, or effusion were classified as positive, which were 
suspicious for lung cancer. Other clinically significant condition 
other than lung cancer and minor abnormality was also recorded 
[11]. Subsequent assessment or management followed general 
clinical practice. As of February 2019, recurrence of primary 
malignancy or occurrence of SMN were reviewed using medical 
records.
3. Lung cancer risk assessment
Six-year risk of lung cancer was calculated using the modified 
lung-cancer risk-prediction model from Prostate, Lung, 
Colorectal, and Ovarian (PLCO) Cancer Screening model 
(PLCOM2012) [12]. The participants were classified into three risk 
groups using the NLST criteria and a 6-year risk-prediction model 
(PLCOM2012): (1) risk group 1, current smokers or former smokers 
within the previous 15 years, aged 55 to 74 years, and with a 
history of at least 30 pack-years of cigarette smoking; (2) risk 
group 2, except the subject who met the criteria of risk group 1, 
current or former smokers, with a history of at least 20 pack-years 
of cigarette smoking and a 6-year risk of lung cancer ≥ 0.0151 
[13]; (3) risk group 3, other patients who did not meet the criteria 
of risk group 1 nor risk group 2.
4. Statistical analyses
The differences of clinicopathologic variables, cancer-related 
factors were analyzed using Pearson’s 2 test, Mann–Whitney 
U-test, Kruskal–Wallis test, and Fisher’s exact test according to the 
lung-cancer risk groups. P–value ＜ 0.05 was considered 
statistically significant. All statistical analyses were performed 
using IBM SPSS ver. 23 for windows (IBM Corp., Armonk, NY, 
USA).
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Table 1. Baseline characteristics (n = 176)
Variable Value
Clinical/social factors
Sex
Male 173 (98.3)
Female   3 (1.7)
Age (yr)  66 (55-79)
BMI (kg/m2) 23.8 (16.1-34.7)
Smoking status
Current  32 (18.2)
Former 144 (81.8)
Smoking intensity (cigarette)  20 (3-60)
Smoking duration (yr)  30 (6-60)
Pack-years  30 (5-135)
Duration of smoking cessation (yr)   9 (0-42)
Hypertension
Yes  65 (36.9)
No 111 (63.1)
Diabetes mellitus
Yes  44 (25.0)
No 132 (75.0)
COPD
Yes  33 (18.8)
No 143 (81.3)
Education status
Less than high school graduate  42 (23.9)
High school graduate  71 (40.3)
College graduate or higher  63 (35.8)
Colorectal cancer-related factors
Location
Right-sided  30 (17.0)
Left-sided 146 (83.0)
Histological differentiation
Adenocarcinoma, well differentiated  32 (18.2)
Adenocarcinoma, moderately differentiated 130 (73.9)
Adenocarcinoma, poorly differentiated   6 (3.4)
Mucinous carcinoma   3 (1.7)
Others   5 (2.8)
Stage
0   1 (0.6)
I  38 (21.6)
II  51 (29.0)
III  77 (43.8)
IV   9 (5.1)
Adjuvant chemotherapy
Yes 123 (69.9)
No  53 (30.1)
Values are presented as number (%) or median (range). BMI, body 
mass index; COPD, chronic obstructive pulmonary disease.
RESULTS
1. Patients characteristics
Between August 2016 and August 2017, 633 long-term 
colorectal cancer survivors visited the survivorship clinic in 
Cancer Prevention Center, Yonsei Cancer Center, Seoul, Republic 
of Korea. Forty-four patients (7.0%) were current smokers, and 
238 patients (37.6%) were former smokers. Among 210 patients 
who met the eligibility criteria, 34 patients refused to receive 
low-dose chest CT screening for lung cancer. Therefore, 176 
patients were finally enrolled in this study. Table 1 showed the 
baseline characteristics of the patients. Median survival time 
from diagnosis of cancer was 63.1 months (range, 50.5-417.2 
months). One hundred seventy-three patients (98.3%) were male, 
and median age was 66 years (range, 55-79 years). 
2. Risk classification according to National Lung 
Screening Trial criteria and PLCOM2012 model
All patients were classified into three risk groups using NLST 
criteria and 6-year risk of lung cancer (PLCOM2012). Risk group 1 
included the individuals with the clinical features similar to NLST 
criteria (n = 79). Risk group 2 released the age limit and selected 
the individuals with higher 6-year risk of lung cancer by 
PLCOM2012 ≥ 0.0151 (n = 36). Risk group 3 was aimed at the 
individuals without significant risk factors, which meant 
moderate to low risk group (n = 61). 
Although most clinical features were not different among the 
risk groups (Supplementary Table 1), median age was higher in 
risk group 2 due to the age limit (55-74 years of age) of NLST 
cohort in risk group 1. Current smokers accounted for 24.1%, 
19.4%, and 9.8% of risk group 1, risk group 2, and risk group 3, 
respectively. Median PLCOM2012 risk score was 0.01655 (range, 
0.00009-0.21732) in all patients, 0.02570 (range, 0.00651-0.21732) 
in risk group 1, 0.02898 (range, 0.01561-0.18717) in risk group 2, 
and 0.00771 (range, 0.00009-0.01534) in risk group 3 (P  ＜ 0.001). 
3. Positive radiologic findings and second malignant 
neoplasm
We found 38 positive findings (non-calcified nodule ≥ 4 mm), 
8 clinically significant findings, 66 minor abnormalities, and 64 
negative findings on low-dose chest CT (Table 2). Positive findings 
were identified in 15 of 79 (19.0%) of risk group 1, in 9 of 36 
(25.0%) of risk group 2, and in 14 of 61 (23.0%) of risk group 3, with 
presentation of median 6 mm (range, 4.3-14.0 mm) sized 
non-calcified nodules. Among 38 patients with positive findings, 
further assessment revealed 3 cases of second primary lung 
cancer, and 1 case of pulmonary metastasis. Second primary lung 
cancers were found in 2 patients of risk group 2, and in 1 patient 
of risk group 3. Surgical specimen of two patients showed 
histology of adenocarcinoma, and one patient was diagnosed 
with small cell lung carcinoma. One patient with pulmonary 
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Table 2. Result of low-dose chest computed tomography screening according to the risk groups (n = 176)
Variable Positive results
Clinically significant abnormality 
not suspicious for lung cancer
No or minor abnormality
Risk group 1a 15 (19.0) 4 (5.1) 60 (75.9)
Risk group 2b 9 (25.0) 2 (5.6) 25 (69.4)
Risk group 3c 14 (23.0) 2 (3.2) 45 (73.8)
Total 38 (21.6) 8 (4.5) 130 (73.9)
Values are presented as number (%). aRisk group 1 includes the individuals who meet the criteria of National Lung Screening Trial (NLST): 
Age 55-74 years and ≥ 30 pack-year history of smoking and smoking cessation ＜ 15 years. bRisk group 2 includes the individuals who 
would not meet the NLST criteria but are possibly related to the similar risk to those of NLST cohort: Age 50 years and ≥ 20 pack-year 
history of smoking and additional risk factors that increase the 6-year risk of lung cancer (PLCOM2012 [Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening model] ≥ 0.0151). cRisk group 3 includes the individuals without risk factors, classified as moderate to low risk group.
Table 3. Occurrence of second malignant neoplasm (SMN) according to the risk groups (n = 176)
Kind of SMN Risk group 1a (n = 79) Risk group 2b (n = 36) Risk group 3c (n = 61) P-value
Colon 0 (0) 2 (5.6) 3 (4.9)    0.086d
Stomach 4 (5.1) 4 (11.1) 0 (0)    0.024d
Kidney 2 (2.5) 1 (2.8) 1 (1.6) ＞ 0.99d
Prostate 1 (1.3) 2 (5.6) 1 (1.6)    0.419d
Lung 0 (0) 2 (5.6) 1 (1.6)    0.091d
Thyroid 2 (2.5) 0 (0) 0 (0)    0.687d
Esophagus 0 (0) 1 (2.8) 0 (0)    0.205d
Head and Neck 1 (1.3) 0 (0) 0 (0) ＞ 0.99
Hepatobiliary 0 (0) 0 (0) 1 (1.6)    0.551d
Hematology 1 (1.3) 0 (0) 1 (1.6) ＞ 0.99
Any kind of SMN 10 (12.7) 11 (30.6) 6 (9.8)    0.016
Values are presented as number (%). aRisk group 1 includes the individuals who meet the criteria of National Lung Screening Trial (NLST): 
Age 55-74 years and ≥ 30 pack-year history of smoking and smoking cessation ＜ 15 years. bRisk group 2 includes the individuals who 
would not meet the NLST criteria but are possibly related to the similar risk to those of NLST cohort: Age 50 years and ≥ 20 pack-year 
history of smoking and additional risk factors that increase the 6-year risk of lung cancer (PLCOM2012 [Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening model] ≥ 0.0151). cRisk group 3 includes the individuals without risk factors, classified as moderate to low risk group. 
dThese values were analyzed using Fisher’s exact tests. 
metastasis had the clinical features of risk group 2. In addition, 
among 176 colorectal cancer survivors, 27 patients were 
diagnosed with any kind of SMN. Common SMNs were colon, 
stomach, kidney, prostate, and lung cancer. In terms of risk 
groups, SMN was most frequently found in risk group 2 (11 of 36 
patients, 30.6%), compared with risk group 1 (12.7%) or risk group 
3 (9.8%) (P = 0.016) (Table 3).
DISCUSSION
Overall risk of SMN is approximately 8.1% for the common 
cancer survivors [3], and lung cancer is one of the most common 
SMNs. In terms of the risk of lung cancer, prior diagnosis of 
malignant tumor was considered as an independent risk factor in 
the lung-cancer prediction models including the Liverpool Lung 
Project risk model [14] and PLCOM2012 model [12]. However, 
adequate method for lung cancer screening in other cancer 
survivors was not well established. In this study, we conducted 
lung cancer screening with low-dose chest CT for colorectal 
cancer survivors with a smoking history. We also attempted to 
find the feasibility of low-dose chest CT screening by analyzing 
the radiologic findings, risk stratification, and clinical outcomes. 
In addition to the favorable result of NLST which changed the 
standard of lung cancer screening methods for high-risk 
individuals [11], recently updated result of NELSON trial also 
presented that low-dose CT screening decreased mortality by 26% 
in men and up to 61% in women with high risk at 10 years [15]. 
With the progress of low-dose chest CT screening in clinical 
practice, several issues surrounding cost-effectiveness [16] and 
overdiagnosis [17] were frequently discussed. To avoid excessive 
CT scan to low-risk individuals, researchers tried to increase 
interval between the screens in the patients with a negative T0 
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(prevalence) screen [18], or apply a personalized screening 
methods according to the risk of lung cancer mortality [19].
Meanwhile, NLST cohort defined the high-risk individuals as 
men or women aged 55 to 74 years with at least a 30 pack-year 
history of cigarette smoking, and, if a former smoker, had quit 
within the past 15 years, and this definition is similarly used in 
many clinical guidelines [5,7-9]. The American Association for 
Thoracic Surgery (AATS) guideline recommended to continue 
screening to age 79 years because of the peak incidence of lung 
cancer (70 years in the United States) and prolonged life 
expectancy. AATS included the individuals aged ≥ 50 years, ≥ 20 
pack-year smoking, and ≥ 5% risk of developing lung cancer 
within 5 years to their screening criteria [9]. The NCCN guideline 
similarly provides additional criteria for the individuals with high 
risk of lung cancer other than cumulative dose of smoking and 
duration of smoking cessation [5]. The PLCO predictive model 
was designed using data collected in the PLCO Cancer Screening 
Trial for ever-smokers [20], and revised to ensure applicability to 
NLST data (PLCOM2012) [12]. PLCOM2012 criteria were known to 
have improved sensitivity (83.0%) and positive predictive value 
(4.0%) compared to NLST criteria [12]. According to the guidelines 
from ATTS and NCCN, we would consider to screen the patients 
older than 74 years of age, and former smoker who stopped 
smoking more than 15 years ago, but with high risk score (i.e., 
6-year risk in PLCOM2012 ≥ 0.0151) [13]. 
In the present study, the proportion of positive result was 
21.6%, and only 3 of which (7.8% of total positive tests) was 
proved to be primary lung cancers. Considering the proportion of 
positive result was 27.3% and the proportion of confirmed lung 
cancer was 3.8 % in T0 round of low-dose CT arm in the NLST [11], 
our results were consistent to those of previous study. However, 
among the participants in risk group 1, who met the criteria of 
NLST, the proportions of positive results and confirmed lung 
cancer were 19.0 % and 0 %, respectively. Instead, 2 lung cancers 
were found in risk group 2, and 1 lung cancer was found in risk 
group 3; Patient#1 was 76-year-old male and current smoker with 
a 54 pack-year history of smoking. Because of the old age (≥ 75 
years of age), he was classified into risk group 2. He was diagnosed 
with small cell lung cancer, and his 6-year risk (PLCOM2012) was 
0.13920. Patient#2 was 78-year-old male and former smoker with 
a 100 pack-year history of smoking and 7 years of smoking 
cessation. He was classified into risk group 2 with 6-year risk 
(PLCOM2012) of 0.11314. He was diagnosed with non-small cell 
lung cancer (adenocarcinoma). Patient#3 was 73-year-old male 
and former smoker with a 15 pack-year history of smoking and 16 
years of smoking cessation. He was classified into risk group 3 
with 6-year PLCOM2012 value of 0.01178. He was diagnosed with 
adenocarcinoma in situ (AIS). 
Although the personal history of malignant tumor increases 
the possibility of lung cancer [12,14], the efficacy of lung cancer 
screening is not fully investigated in cancer survivors. Because 
most prospective large-scale clinical trials excluded the 
participation of other cancer survivors, clinical outcome of 
screening program in cancer survivors had generally been 
estimated in real-world practice [21]. Despite its small sample 
size, this study has clinical meaning to apply the low-dose chest 
CT screening to colorectal cancer survivors, and to analyze the 
clinical outcome with risk groups using NLST criteria and 
well-designed lung-cancer risk prediction model (PLCOM2012). 
Among 176 ever-smoker colorectal cancer survivors, we found 3 
patients with second primary lung cancer. However, two of the 
patients did not meet NLST criteria, but had high PLCOM2012 score 
with age older than 74 years. Moreover, another one patient with 
AIS even had low PLCOM2012 prediction score. In Korea, in 
common with United States documented in AATS guidelines, the 
peak age of incidence of lung cancer was 70 years, and average life 
expectancy was 79 years of age in men and 85 years of age in 
women [22]. Therefore, we carefully suggest that lung cancer 
screening could be considered in the patients aged 75-80 years 
with good performance but high risk for lung cancer. Further, we 
need to develop a novel lung-cancer risk prediction model 
reflecting the different epidemiology of lung cancer in Asia. 
Low-dose chest CT screening for lung cancer is feasible as a 
screening method for SMN in Korean colorectal cancer survivors. 
However, the screening criteria should be more enhanced and 
personalized. Well-designed clinical trials using personalized 
cancer risk-prediction tools are needed for cancer survivors.
ACKNOWLEDGMENTS
This study was supported by a grant from the National R&D 
Program for Cancer Control, Ministry of Health & Welfare, 
Republic of Korea (1631020).
CONFLICTS OF INTEREST
No potential conflicts of interest were disclosed.
Supplementary Materials
Supplementary materials can be found via https://doi.org/ 
10.15430/JCP.2019.24.1.48.
 Ji Soo Park, et al: Low-dose Chest CT Screening for Colorectal Cancer Survivors 53
REFERENCES
1. Jung KW, Won YJ, Kong HJ, Lee ES; Community of Population- 
Based Regional Cancer Registries. Cancer statistics in Korea: in-
cidence, mortality, survival, and prevalence in 2015. Cancer Res 
Treat 2018;50:303-16.
2. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards 
BK, et al. New malignancies among cancer survivors: Seer cancer 
registries, 1973-2000. Bethesda, National Cancer Institute, 2006.
3. Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L, et al. 
Risk of second primary malignancies among cancer survivors in 
the United States, 1992 through 2008. Cancer 2016;122:3075-86.
4. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone 
CB, et al. Cancer survivorship–genetic susceptibility and second 
primary cancers: research strategies and recommendations. J 
Natl Cancer Inst 2006;98:15-25.
5. National Comprehensive Cancer Network. NCCN clinical practice 
guidelines in oncology: lung cancer screening version 2. https:// 
www.nccn.org/professionals/physician_gls/pdf/lung_screening. 
pdf. Accessed on March 21, 2019.  
6. Wender R, Fontham ET, Barrera E Jr, Colditz GA, Church TR, 
Ettinger DS, et al. American Cancer Society lung cancer screening 
guidelines. J Natl Cancer Inst 2013;63:107-17.
7. Moyer VA. Screening for lung cancer: U.S. Preventive Services 
Task Force recommendation statement. Ann Intern Med 2014; 
160:330-8.
8. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for 
lung cancer: diagnosis and management of lung cancer, 3rd ed: 
American College of Chest Physicians evidence-based clinical 
practice guidelines. Chest 2013;143:e78S-92S.
9. Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee 
S, et al. The American Association for Thoracic Surgery guide-
lines for lung cancer screening using low-dose computed tomog-
raphy scans for lung cancer survivors and other high-risk groups. 
J Thorac Cardiovasc Surg 2012;144:33-8.
10. Jang SH, Sheen SS, Kim HY, Yim HW, Kim JW, Park IG, et al. The 
Korean guideline for lung cancer screeningung cancer screening. 
J Korean Med Assoc 2015;58:291-301.
11. National Lung Screening Trial Research Team, Aberle DR, Adams 
AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer 
mortality with low-dose computed tomographic screening. N 
Engl J Med 2011;365:395-409.
12. Tammemägi MC, Katki HA, Hocking WG, Church TR, Caporaso N, 
Kvale PA, et al. Selection criteria for lung-cancer screening. N 
Engl J Med 2013;368:728-36.
13. Tammemägi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, 
Riley TL, et al. Evaluation of the lung cancer risks at which to 
screen ever- and never-smokers: screening rules applied to the 
PLCO and NLST cohorts. PLoS Med 2014;11:e1001764.
14. Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy 
SW, et al. The LLP risk model: an individual risk prediction mod-
el for lung cancer. Br J Cancer 2008;98:270-6.
15. De Koning H, Van Der Aalst C, Ten Haaf K, Oudkerk M. Effects of 
volume CT lung cancer screening: mortality results of the 
NELSON randomised-controlled population based trial. J Thorac 
Oncol 2018;13:S185.
16. Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, et 
al. Cost-effectiveness of CT screening in the National Lung 
Screening Trial. N Engl J Med 2014;371:1793-802.
17. Patz EF Jr, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemägi 
MC, et al. Overdiagnosis in low-dose computed tomography 
screening for lung cancer. JAMA Intern Med 2014;174:269-74.
18. Patz EF Jr, Greco E, Gatsonis C, Pinsky P, Kramer BS, Aberle DR. 
Lung cancer incidence and mortality in National Lung Screening 
Trial participants who underwent low-dose CT prevalence 
screening: a retrospective cohort analysis of a randomised, multi-
centre, diagnostic screening trial. Lancet Oncol 2016;17:590-9.
19. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, 
Korch M, et al. Targeting of low-dose CT screening according to 
the risk of lung-cancer death. N N Engl J Med 2013;369:245-54.
20. Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, 
Church TR, et al. Lung cancer risk prediction: prostate, lung, col-
orectal and ovarian cancer screening trial models and validation J 
Natl Cancer Inst 2011;103:1058-68.
21. Erkmen CP, Kaiser LR, Ehret AL. Lung cancer screening: should 
we be excluding people with previous malignancy? World J 
Respirol 2016;6:1-13.
22. Choi CM, Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, et al. Report 
of the Korean Association of Lung Cancer Registry (KALC-R), 
2014 [published online ahead of print February 25, 2019]. Cancer 
Res Treat. doi: 10.4143/crt.2018.704.
